Featured Jobs
|
Internal Channel Sales Team Lead July Business Services
|
|
Mergers & Acquisition Specialist Compass
|
|
Compass
|
|
Relationship Manager – Defined Contributions Daybright Financial
|
|
Attorney - ERISA, Benefits, & PRT Securian Financial Group
|
|
Senior Client Service Specialist EPIC RPS
|
|
EPIC RPS
|
|
Regional Sales Director-Mid Atlantic July Business Services
|
|
Daybright Financial
|
|
Director, Strategic Accounts and Channel Development July Business Services
|
|
Independent Retirement
|
|
Daybright Financial
|
|
Automotive Industries Trust Funds
|
|
Regional Sales Director-Heartland July Business Services
|
|
Stones River Consulting
|
|
The Pension Source
|
|
Experienced Employee Benefits Attorney Shipman & Goodwin LLP
|
|
Nova 401(k) Associates
|
|
Independent Retirement
|
|
Pentegra
|
Free Newsletters
“BenefitsLink continues to be the most valuable resource we have at the firm.”
-- An attorney subscriber
|
|
| Webinars and Podcasts |
> | Upcoming | On-Demand |
| Conferences | > | Upcoming | Grouped by Location |
| All Webinars, Podcasts and Conferences | > | Upcoming | Grouped by Sponsor |
View More Ropes & Gray Webinars, Podcasts and Conferences
Non-Binding Guidance: The Administration's Focus on Direct-to-Consumer Prescription Drug AdvertisingRopes & Gray |
|
Oct. 6, 2025 On-Demand Podcast |
|
In this episode of Non-binding Guidance, Greg Levine and Josh Oyster, partners in Ropes & Gray’s life sciences regulatory and compliance practice group, are joined by Kellie Combs, partner and chair of Ropes & Gray’s life sciences regulatory and compliance practice group, to discuss the Trump administration’s recent crackdown on direct-to-consumer (DTC) prescription drug advertising. The conversation explores the coordinated actions by HHS and FDA, aggressive enforcement measures, proposed rulemaking to reshape DTC broadcast ads, and the use of AI in regulatory oversight. The hosts examine the impact of recent FDA enforcement letters, challenges in digital and social media promotion, and the shifting compliance landscape for pharmaceutical companies. This episode offers practical guidance for life sciences companies navigating this rapidly changing regulatory environment. |